| Literature DB >> 30960764 |
Young-Hoon Jeong1, Hye Min Oh2, Man Ryul Lee3, C-Yoon Kim4, Chanyang Joo5, Soon-Jung Park6, Yun-Ho Song7, Changhee Kang8, Hyung-Min Chung9, Sun-Woong Kang10,11, Kang Moo Huh12, Sung-Hwan Moon13.
Abstract
Adipose-derived mesenchymal stem cells (AD-MSCs) have been studied as desirable cell sources for regenerative medicine and therapeutic application. However, it has still remained a challenge to obtain enough adequate and healthy cells in large quantities. To overcome this limitation, various biomaterials have been used to promote expansion of MSCs in vitro. Recently, hexanoyl glycol chitosan (HGC) was introduced as a new biomaterial for various biomedical applications, in particular 3D cell culture, because of its biodegradability, biocompatibility, and other promising biofunctional properties. In this study, the effect of HGC on the proliferation of AD-MSCs was examined in vitro, and its synergistic effect with basic fibroblast growth factor (bFGF), which has been widely used to promote proliferation of cells, was evaluated. We found that the presence of HGC increased the proliferative capacity of AD-MSCs during long-term culture, even at low concentrations of bFGF. Furthermore, it suppressed the expression of senescence-related genes and improved the mitochondrial functionality. Taken all together, these findings suggest that the HGC demonstrate a potential for sustained growth of AD-MSCs in vitro.Entities:
Keywords: basic fibroblast growth factor; hexanoyl glycol chitosan; mesenchymal stem cell
Year: 2018 PMID: 30960764 PMCID: PMC6404012 DOI: 10.3390/polym10080839
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Characterization of hexanoyl glycol chitosan. (a) Synthesis procedure of hexanoyl glycol chitosan (HGC)36.9; (b) 1H NMR spectra and (c) FT-IR spectra of HGC36.9 and glycol chitosan (GC).
Figure 2Characterization of adipose-derived mesenchymal stem cells (AD-MSCs) used for experiments. (a) Positive markers for CD44, CD73, CD90, and CD105, negative markers for CD31 and CD34; (b) Staining for multilineage differentiation of AD-MSCs.
Figure 3Investigation of optimal hexanoyl glycol chitosan (HGC) concentration. (a) experimental scheme; (b) cell number of AD-MSCs at day four (passage 5); ** p < 0.01 relative to the control; (c) cell morphology and density of the control and 1 μg/mL of HGC at day four (passage 5); (d) Comparison of population doubling time at passage 5 (the control) and the control and 1 μg/mL of HGC group at passage 10.
Figure 4Comparison of proliferative capacity between HGC combined with basic fibroblast growth factor (bFGF) groups and non-treated groups. (a) Experimental scheme following various concentration of bFGF treatment with 1 μg/mL of HGC; (b) Daily incubated cell morphology picture of AD-MSCs at passage 5; (c) Population doubling time at passages 5 and 10; and (d) cell cycle analysis. ** p < 0.01, and *** p < 0.001 relative to the control.
Figure 5The analysis of metabolic functionality of AD-MSCs at passage 10. (a) The measurement of oxygen consumption rate following oligomycin, FCCP, antimycin A, and rotenone treatment; (b) ATP production; (c) maximum respiration; (d) The measurement of extracellular glycolytic acidification following glucose, oligomycin, and 2-DG treatment. Glycolytic function displayed an increased extracellular acidification rate in control and 5 ng/mL bFGF-only treated group; (e) glycolysis and (f) glycolytic capacity. * p < 0.05 and ** p < 0.01 relative to the control. FCCP: carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone, 2-DG: 2-deoxy-glucose.
Figure 6Quantitative real-time polymerase chain reaction (RT-PCR) analysis for senescence markers. * p < 0.05, ** p < 0.01, and *** p < 0.001 relative to the control. # p < 0.05 relative to bFGF-only group.
Figure 7Characterization of AD-MSCs phenotypes by fluorescence-activated cell sorting (FACS) after long-term culture (passage 10).